{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:25:14Z","timestamp":1794918314760,"version":"4.9.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001648","name":"European Foundation for the Study of Diabetes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001648","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.biopha.2024.116477","type":"journal-article","created":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T13:40:25Z","timestamp":1711287625000},"page":"116477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Empagliflozin mitigates cardiac hypertrophy through cardiac RSK\/NHE-1 inhibition"],"prefix":"10.1016","volume":"174","author":[{"given":"Sha","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7740-6188","authenticated-orcid":false,"given":"Kenneth","family":"Overberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakiya","family":"Ghouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus W.","family":"Hollmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina C.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9433-6119","authenticated-orcid":false,"given":"Ruben","family":"Coronel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coert J.","family":"Zuurbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10254","key":"10.1016\/j.biopha.2024.116477_bib1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.biopha.2024.116477_bib2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCULATIONAHA.122.061688","article-title":"Sodium glucose cotransporter-2 inhibitor empagliflozin reduces infarct size independently of sodium glucose cotransporter-2","volume":"147","author":"Chen","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.biopha.2024.116477_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-022-01480-1","article-title":"Direct cardiac effects of SGLT2 inhibitors","volume":"21","author":"Chen","year":"2022","journal-title":"Cardiovasc Diabetol."},{"issue":"21","key":"10.1016\/j.biopha.2024.116477_bib4","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.biopha.2024.116477_bib5","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ejhf.1473","article-title":"Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction","volume":"21","author":"Yurista","year":"2019","journal-title":"Eur. J. Heart Fail"},{"issue":"15","key":"10.1016\/j.biopha.2024.116477_bib6","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116477_bib7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116477_bib8","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/bjp.2008.189","article-title":"Chronic inhibition of the Na+\/H+ - exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling","volume":"154","author":"Baartscheer","year":"2008","journal-title":"Br. J. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2024.116477_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.coph.2007.12.007","article-title":"Targeting Na+\/H+ exchanger regulation for cardiac protection: a RSKy approach?","volume":"8","author":"Avkiran","year":"2008","journal-title":"Curr. Opin. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2024.116477_bib10","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.yjmcc.2008.01.005","article-title":"The role of NHE-1 in myocardial hypertrophy and remodelling","volume":"44","author":"Karmazyn","year":"2008","journal-title":"J. Mol. Cell Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116477_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cardiores.2004.09.024","article-title":"Chronic inhibition of Na+\/H+-exchanger attenuates cardiac hypertrophy and prevents cellular remodeling in heart failure","volume":"65","author":"Baartscheer","year":"2005","journal-title":"Cardiovasc Res"},{"issue":"7","key":"10.1016\/j.biopha.2024.116477_bib12","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1161\/01.RES.0000014966.97486.C0","article-title":"Inhibition of Na(+)-H(+) exchange prevents hypertrophy, fibrosis, and heart failure in beta(1)-adrenergic receptor transgenic mice","volume":"90","author":"Engelhardt","year":"2002","journal-title":"Circ. Res"},{"issue":"3","key":"10.1016\/j.biopha.2024.116477_bib13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits.","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.biopha.2024.116477_bib14","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.biopha.2024.116477_bib15","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1002\/ehf2.13024","article-title":"Empagliflozin inhibits Na(+) \/H(+) exchanger activity in human atrial cardiomyocytes","volume":"7","author":"Trum","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.biopha.2024.116477_bib16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3389\/fphar.2015.00270","article-title":"Counteracting Protein Kinase Activity in the Heart: The Multiple Roles of Protein Phosphatases","volume":"6","author":"Weber","year":"2015","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2024.116477_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.592233","article-title":"Empagliflozin Decreases Lactate Generation in an NHE-1 Dependent Fashion and Increases \u03b1-Ketoglutarate Synthesis From Palmitate in Type II Diabetic Mouse Hearts","volume":"7","author":"Zhang","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.biopha.2024.116477_bib18","doi-asserted-by":"crossref","first-page":"8928","DOI":"10.1038\/ncomms9928","article-title":"STAT5-regulated microRNA-193b controls haematopoietic stem and progenitor cell expansion by modulating cytokine receptor signalling","volume":"6","author":"Haetscher","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2024.116477_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-1-4939-9036-8_13","article-title":"Profiling Activity of Cellular Kinases in Migrating T-Cells","volume":"1930","author":"Chirumamilla","year":"2019","journal-title":"Methods Mol. Biol."},{"issue":"5","key":"10.1016\/j.biopha.2024.116477_bib20","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"Omics"},{"issue":"1","key":"10.1016\/j.biopha.2024.116477_bib21","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20130094","article-title":"A combination of SILAC and nucleotide acyl phosphate labelling reveals unexpected targets of the Rsk inhibitor BI-D1870","volume":"34","author":"Edgar","year":"2014","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.biopha.2024.116477_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1471-2199-11-57","article-title":"Experimental comparison of relative RT-qPCR quantification approaches for gene expression studies in poplar","volume":"11","author":"Regier","year":"2010","journal-title":"BMC Mol. Biol."},{"issue":"16","key":"10.1016\/j.biopha.2024.116477_bib23","first-page":"759","article-title":"Immunoblot analysis","author":"Gallagher","year":"2008","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.biopha.2024.116477_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112515","article-title":"Empagliflozin reduces oxidative stress through inhibition of the novel inflammation\/NHE\/[Na(+)](c)\/ROS-pathway in human endothelial cells.","volume":"146","author":"Uthman","year":"2022","journal-title":"Biomed. Pharm."},{"issue":"9","key":"10.1016\/j.biopha.2024.116477_bib25","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.cellsig.2014.04.018","article-title":"Early NADPH oxidase-2 activation is crucial in phenylephrine-induced hypertrophy of H9c2 cells","volume":"26","author":"Hahn","year":"2014","journal-title":"Cell Signal"},{"issue":"6","key":"10.1016\/j.biopha.2024.116477_bib26","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s11010-022-04411-6","article-title":"Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression","volume":"477","author":"Abdulrahman","year":"2022","journal-title":"Mol. Cell Biochem"},{"issue":"1","key":"10.1016\/j.biopha.2024.116477_bib27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3892\/etm.2021.10147","article-title":"SGLT2 promotes cardiac fibrosis following myocardial infarction and is regulated by miR-141","volume":"22","author":"Li","year":"2021","journal-title":"Exp. Ther. Med"},{"issue":"3","key":"10.1016\/j.biopha.2024.116477_bib28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4070\/kcj.2020.0303","article-title":"Sodium\/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction","volume":"51","author":"Lee","year":"2021","journal-title":"Korean Circ. J."},{"issue":"2","key":"10.1016\/j.biopha.2024.116477_bib29","doi-asserted-by":"crossref","DOI":"10.1152\/ajpheart.00736.2019","article-title":"New insight in understanding the contribution of SGLT1 in cardiac glucose uptake: evidence for a truncated form in mice and humans","volume":"320","author":"Fert\u00e9","year":"2021","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"11","key":"10.1016\/j.biopha.2024.116477_bib30","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1093\/emboj\/17.11.3052","article-title":"A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers","volume":"17","author":"Bischoff","year":"1998","journal-title":"Embo J."},{"key":"10.1016\/j.biopha.2024.116477_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101771","article-title":"Metabolic protein kinase signalling in neuroblastoma","volume":"75","author":"Smiles","year":"2023","journal-title":"Mol. Metab."},{"issue":"23","key":"10.1016\/j.biopha.2024.116477_bib32","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.3390\/cancers14235811","article-title":"SGLT-2 Inhibitors in Cancer Treatment-Mechanisms of Action and Emerging New Perspectives","volume":"14","author":"Dutka","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"42","key":"10.1016\/j.biopha.2024.116477_bib33","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1074\/jbc.REV120.008387","article-title":"Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks","volume":"295","author":"Perry","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2024.116477_bib34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/iub.1383","article-title":"RSK3: A regulator of pathological cardiac remodeling","volume":"67","author":"Martinez","year":"2015","journal-title":"IUBMB Life"},{"issue":"21","key":"10.1016\/j.biopha.2024.116477_bib35","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.105.563486","article-title":"Inhibiting p90 ribosomal S6 kinase prevents (Na+)-H+ exchanger-mediated cardiac ischemia-reperfusion injury","volume":"113","author":"Maekawa","year":"2006","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.biopha.2024.116477_bib36","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1002\/ehf2.13065","article-title":"The role and molecular mechanism of FoxO1 in mediating cardiac hypertrophy","volume":"7","author":"Yu","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"3","key":"10.1016\/j.biopha.2024.116477_bib37","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1039\/D0FO02387F","article-title":"Resveratrol attenuates dapagliflozin-induced renal gluconeogenesis via activating the PI3K\/Akt pathway and suppressing the FoxO1 pathway in type 2 diabetes","volume":"12","author":"Sun","year":"2021","journal-title":"Food Funct."},{"issue":"6","key":"10.1016\/j.biopha.2024.116477_bib38","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00125-007-0628-x","article-title":"Enhanced activity of the myocardial Na+\/H+ exchanger contributes to left ventricular hypertrophy in the Goto-Kakizaki rat model of type 2 diabetes: critical role of Akt.","volume":"50","author":"Darmellah","year":"2007","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.biopha.2024.116477_bib39","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/dmrr.689","article-title":"Role of endothelin-1, sodium hydrogen exchanger-1 and mitogen activated protein kinase (MAPK) activation in glucose-induced cardiomyocyte hypertrophy","volume":"23","author":"Chen","year":"2007","journal-title":"Diabetes Metab. Res Rev."},{"issue":"10","key":"10.1016\/j.biopha.2024.116477_bib40","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1038\/s41401-022-00885-8","article-title":"Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1\/MAPK signaling","volume":"43","author":"Lin","year":"2022","journal-title":"Acta Pharm. Sin."},{"issue":"6","key":"10.1016\/j.biopha.2024.116477_bib41","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s12276-023-01002-3","article-title":"Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction","volume":"55","author":"Kim","year":"2023","journal-title":"Exp. Mol. Med"},{"issue":"680","key":"10.1016\/j.biopha.2024.116477_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abp9952","article-title":"SGLT2 inhibitor ameliorates endothelial dysfunction associated with the common ALDH2 alcohol flushing variant","volume":"15","author":"Guo","year":"2023","journal-title":"Sci. Transl. Med"},{"issue":"5","key":"10.1016\/j.biopha.2024.116477_bib43","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s13238-020-00809-4","article-title":"Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis","volume":"13","author":"Jiang","year":"2022","journal-title":"Protein Cell"},{"issue":"1","key":"10.1016\/j.biopha.2024.116477_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12933-023-01756-0","article-title":"Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis","volume":"22","author":"Chung","year":"2023","journal-title":"Cardiovasc Diabetol."},{"issue":"14","key":"10.1016\/j.biopha.2024.116477_bib45","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1093\/cvr\/cvaa323","article-title":"Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower [Na+]i in the heart","volume":"117","author":"Chung","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.biopha.2024.116477_bib46","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijcard.2022.06.054","article-title":"Acute SGLT-2i treatment improves cardiac efficiency during myocardial ischemia independent of Na(+)\/H(+) exchanger-1.","volume":"363","author":"Baker","year":"2022","journal-title":"Int J. Cardiol."},{"issue":"14","key":"10.1016\/j.biopha.2024.116477_bib47","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1093\/cvr\/cvab129","article-title":"Sodium-glucose co-transporter 2 inhibitor empagliflozin inhibits the cardiac Na+\/H+ exchanger 1: persistent inhibition under various experimental conditions","volume":"117","author":"Zuurbier","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.biopha.2024.116477_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1179131","article-title":"Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Physiol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116477_bib49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/1074248415591700","article-title":"The RSK Inhibitor BIX02565 Limits Cardiac Ischemia\/Reperfusion Injury","volume":"21","author":"Shi","year":"2016","journal-title":"J. Cardiovasc Pharm. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2024.116477_bib50","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1124\/mol.106.029900","article-title":"Evidence for direct regulation of myocardial Na+\/H+ exchanger isoform 1 phosphorylation and activity by 90-kDa ribosomal S6 kinase (RSK): effects of the novel and specific RSK inhibitor fmk on responses to alpha1-adrenergic stimulation","volume":"71","author":"Cuello","year":"2007","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2024.116477_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122230","article-title":"Na+\/H+ exchanger isoform 1 induced cardiomyocyte hypertrophy involves activation of p90 ribosomal s6 kinase","volume":"10","author":"Jaballah","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.biopha.2024.116477_bib52","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1152\/physiolgenomics.00133.2017","article-title":"Na(+)\/H(+) exchanger isoform 1-induced osteopontin expression facilitates cardiac hypertrophy through p90 ribosomal S6 kinase","volume":"50","author":"Abdulrahman","year":"2018","journal-title":"Physiol. Genom."},{"issue":"1","key":"10.1016\/j.biopha.2024.116477_bib53","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12918-016-0303-2","article-title":"Signaling cascades transmit information downstream and upstream but unlikely simultaneously","volume":"10","author":"Catozzi","year":"2016","journal-title":"BMC Syst. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116477_bib54","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s42003-023-04663-y","article-title":"The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice","volume":"6","author":"Choi","year":"2023","journal-title":"Commun. Biol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116477_bib55","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10557-021-07311-x","article-title":"Empagliflozin Ameliorates Ouabain-Induced Na(+) and Ca(2+) Dysregulations in Ventricular Myocytes in an Na(+)-Dependent Manner.","volume":"37","author":"Peng","year":"2023","journal-title":"Cardiovasc Drugs Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.116477_bib56","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1161\/CIRCRESAHA.112.276162","article-title":"Anchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy","volume":"112","author":"Li","year":"2013","journal-title":"Circ. Res"},{"key":"10.1016\/j.biopha.2024.116477_bib57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.yjmcc.2021.12.007","article-title":"Systematic transcriptomic and phenotypic characterization of human and murine cardiac myocyte cell lines and primary cardiomyocytes reveals serious limitations and low resemblances to adult cardiac phenotype","volume":"165","author":"Onodi","year":"2022","journal-title":"J. Mol. Cell Cardiol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116477_bib58","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bbamcr.2014.11.015","article-title":"H9c2 and HL-1 cells demonstrate distinct features of energy metabolism, mitochondrial function and sensitivity to hypoxia-reoxygenation","volume":"1853","author":"Kuznetsov","year":"2015","journal-title":"Biochim Biophys. Acta"},{"issue":"6","key":"10.1016\/j.biopha.2024.116477_bib59","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10557-018-6837-3","article-title":"Dapagliflozin Attenuates Na(+)\/H(+) Exchanger-1 in Cardiofibroblasts via AMPK Activation.","volume":"32","author":"Ye","year":"2018","journal-title":"Cardiovasc Drugs Ther."},{"issue":"2","key":"10.1016\/j.biopha.2024.116477_bib60","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","article-title":"SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3\/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovasc Drugs Ther."},{"issue":"4","key":"10.1016\/j.biopha.2024.116477_bib61","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10557-021-07190-2","article-title":"Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy","volume":"36","author":"Yerra","year":"2022","journal-title":"Cardiovasc Drugs Ther."},{"issue":"7","key":"10.1016\/j.biopha.2024.116477_bib62","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ejhf.1473","article-title":"Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction","volume":"21","author":"Yurista","year":"2019","journal-title":"Eur. J. Heart Fail"},{"issue":"36","key":"10.1016\/j.biopha.2024.116477_bib63","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1093\/eurheartj\/ehaa419","article-title":"A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial","volume":"41","author":"Brown","year":"2020","journal-title":"Eur. Heart J."},{"issue":"21","key":"10.1016\/j.biopha.2024.116477_bib64","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.biopha.2024.116477_bib65","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.biopha.2024.116477_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.680758","article-title":"Polydatin Reduces Cardiotoxicity and Enhances the Anticancer Effects of Sunitinib by Decreasing Pro-Oxidative Stress, Pro-Inflammatory Cytokines, and NLRP3 Inflammasome Expression","volume":"11","author":"Quagliariello","year":"2021","journal-title":"Front Oncol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224003615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224003615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T22:50:44Z","timestamp":1782341444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224003615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":66,"alternative-id":["S0753332224003615"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116477","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin mitigates cardiac hypertrophy through cardiac RSK\/NHE-1 inhibition","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116477"}}